A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Completed · Phase 2 · Has a placebo group
Conditions studied: Hypothalamic Obesity
In brief
The goal of this study is to determine how well LB54640 works and how safe it is in patients with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older with HO. Patients will take an oral daily dose of either LB54640 (low, middle, or high dose) or placebo through Week 14. Eligible patients who consent to continue in the study after Week 14 will take an oral daily dose of LB54640 through Week 56.
Key facts
- Study ID
- NCT06046443
- Run by
- Rhythm Pharmaceuticals, Inc.
- People needed
- 28
- Starts
- 2024-07-11
- Expected to finish
- 2026-02-09
- Last updated by the study team
- 2026-02-12
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital Colorado — Aurora, Colorado, United States
- University of Iowa Children's Hospital — Iowa City, Iowa, United States
- Tufts Medical Center — Boston, Massachusetts, United States
- Columbia University — New York, New York, United States
- The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
- Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Birmingham Women's and Children's NHS Foundation Trust — Birmingham, United Kingdom
- University of Cambridge — Cambridge, United Kingdom
- Great Ormond Street Hospital for Children — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.